Investigating a new treatment for recurrent brain tumors using a viral vector and a prodrug.
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
This study is looking at a new treatment for people with tough brain tumors called glioblastoma or anaplastic astrocytoma, using a special combination of therapies to see if it can help them live longer and fight their tumors better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-10888393 on NIH RePORTER |
What this research studies
This research focuses on patients with recurrent glioblastoma or anaplastic astrocytoma, two aggressive types of brain tumors. It aims to evaluate the effectiveness of a novel treatment combining a retroviral vector, DB107, with the prodrug 5-fluorocytosine (5-FC). The approach involves using a biomarker to identify patients who are most likely to respond positively to this therapy. By selectively targeting tumor cells, this treatment hopes to improve survival rates and enhance the immune response against the tumor.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with recurrent glioblastoma or anaplastic astrocytoma.
Not a fit: Patients with low-grade gliomas or those who have not experienced recurrence may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients with recurrent high-grade gliomas.
How similar studies have performed: Previous studies using similar viral vector approaches have shown promising results in improving survival rates for select patient populations.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Shah, Ashish Harish — University of Miami School of Medicine
- Study coordinator: Shah, Ashish Harish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.